Classical ICIs, such as programmed cell death protein-1 (PD-1), PD-L1, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and lymphocyte activation gene-3 (LAG-3) inhibitors, have been approved for the treatment of various cancers. Here, CTLA4 is linked to cancer.